Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 12/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TNF | P01375 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2696231 | 0.89 | CMA1 (0.43) | CMA1PTGDR2TP53MEN1ALDH1A1 | |
| SCHEMBL2695228 | 0.88 | CMA1 (0.55) | CMA1CYP2C9PTGS1SLC6A4CYP2C19 | |
| SCHEMBL2698950 | 0.84 | CMA1 (0.43) | CMA1ADORA2BMAPT | |
| SCHEMBL2696996 | 0.82 | CMA1 (0.55) | CMA1 | |
| SCHEMBL2698201 | 0.82 | CMA1 (0.55) | CMA1 | |
| SCHEMBL3699071 | 0.73 | CMA1 (0.45) | CMA1ALDH1A1MAPT | |
| SCHEMBL3699074 | 0.73 | CMA1 (0.45) | CMA1ALDH1A1MAPT | |
| SCHEMBL2697953 | 0.73 | CMA1 (0.59) | CMA1HTR1DOPRK1 | |
| SCHEMBL2697949 | 0.73 | CMA1 (0.59) | CMA1HTR1DOPRK1 | |
| SCHEMBL2697474 | 0.73 | CMA1 (0.45) | CMA1TP53ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501749-B2 | Azaquinazolinediones chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-06 | — | — | US | disclosed |
| US-20120108597-A1 | Azaquinazolinediones Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108597-A1 | Azaquinazolinediones Chymase Inhibitors | CMA1, SERPINB1, CTSC | CMA1 1/4885CYP2C9 2391/4885PTGS1 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.